Level Bio
Logotype for Level Bio

Level Bio (LEVBIO) investor relations material

Level Bio Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Level Bio
Q3 2026 earnings summary22 Oct, 2026

Executive summary

  • Q3 revenue rose 28% YoY to 8,644 KSEK; comparable growth excluding CyberGene was 59%, while gross margin fell to 40%.

  • Techtum Lab drove growth; priorities include Nordic expansion, portfolio development and profitability.

Financial highlights

  • Q3 revenue was 8,644 KSEK vs 6,750 KSEK; excluding CyberGene’s prior-year contribution, sales were 8,644 KSEK vs 5,432 KSEK, up 59%.

  • Q3 gross profit was 3,415 KSEK vs 3,787 KSEK; operating loss was 310 KSEK vs 207 KSEK, and net loss was 348 KSEK vs 164 KSEK.

  • 9M revenue rose 17% to 26,841 KSEK from 22,939 KSEK; growth was 31% excluding CyberGene. Gross profit was 12,452 KSEK.

  • 9M operating loss narrowed to 652 KSEK from 2,599 KSEK; result after financial items was 5,684 KSEK vs a loss of 2,649 KSEK, impacted by the disposal.

  • Q3 cash flow was -11 KSEK vs +16 KSEK YoY; 9M cash flow was -2,418 KSEK vs +496 KSEK.

Outlook and guidance

  • Strategy centers on Techtum Lab as a platform for profitable growth, growing distribution sales and reaching profitability.

  • Plans include establishing local presence across Nordic countries through hiring and/or acquisitions, and expanding sales in all Nordic markets.

  • Q4 priorities are sales execution, Nordic expansion and profitability; portfolio and pricing decisions will balance growth with margin.

  • CyberGene’s divestment creates comparison effects expected to persist through Q1 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Level Bio earnings date

Logotype for Level Bio
Q4 202618 Feb, 2027
Level Bio
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Level Bio earnings date

Logotype for Level Bio
Q4 202618 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Level Bio is a biotechnology company focused on the development of innovative solutions in the life sciences sector. The company engages in research and product development aimed at addressing challenges in healthcare, leveraging advanced technologies and scientific expertise. Level Bio serves industries such as pharmaceuticals, diagnostics, and medical research with applications designed to improve patient care and treatment outcomes. The company is headquartered in Lund, Sweden, and its shares are listed on the Spotlight Stock Market.